Vol 5, No 3 (2019)
Case report
Published online: 2019-09-19
Zespół antyfosfolipidowy — opis przypadku i przegląd literatury
DOI: 10.5603/FR.2019.0015
Forum Reumatol 2019;5(3):137-143.
Abstract
Zespół antyfosfolipidowy (APS, antiphospholipid syndrome) jest chorobą autoimmunologiczną charakteryzującą się występowaniem epizodów żylnej choroby zatorowo-zakrzepowej i/lub zakrzepicy tętniczej oraz niepowodzeń położniczych z towarzyszącą obecnością przeciwciał antyfosfolipidowych (APLA, antyphospholipid antibodies). W artykule omówiono obraz choroby oraz zalecenia dotyczące leczenia na podstawie opisu przypadku 43-letniej pacjentki. Przedstawiono również wyniki prac oceniających skuteczność nowych leków przeciwkrzepliwych, tak zwanych non-vitamin K oral anticoagulants (NOACs) u pacjentów z rozpoznaniem APS oraz omówiono wykorzystanie innych leków wpływających pośrednio na procesy zakrzepowe.
Forum Reumatol. 2019, tom 5, nr 3: 137–143
Keywords: zespół antyfosfolipidowyprzeciwciała antyfosfolpidowe
References
- Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006; 4(2): 295–306.
- Hernández-Molina G, Espericueta-Arriola G, Cabral AR. The role of lupus anticoagulant and triple marker positivity as risk factors for rethrombosis in patients with primary antiphospholipid syndrome. Clin Exp Rheumatol. 2013; 31(3): 382–388.
- Hughes GR, Khamasta MA, et al. Seronegative antiphospholipid syndrome. Ann Rheum Dis. 2003; 62(12): 1127.
- Nayfe R, Uthman I, Aoun J, et al. Seronegative antiphospholipid syndrome. Rheumatology (Oxford). 2013; 52(8): 1358–1367.
- Bizzaro N, Ghirardello A, Zampieri S, et al. Anti-prothrombin antibodies predict thrombosis in patients with systemic lupus erythematosus: a 15-year longitudinal study. J Thromb Haemost. 2007; 5(6): 1158–1164.
- Asherson RA, Cervera R, de Gr, et al. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines, Lupus. 2003; 12(7): 530–4.
- Simchen MJ, Dulitzki M, Rofe G, et al. High positive antibody titers and adverse pregnancy outcome in women with antiphospholipid syndrome. Acta Obstet Gynecol Scand. 2011; 90(12): 1428–1433.
- Ruiz-Irastorza G, Cuadrado MJ, Ruiz-Arruza I, et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: Report of a Task Force at the 13th International Congress on Antiphospholipid Antibodies. Lupus. 2011; 20(2): 206–18.
- Lockwood Ch, Lockshin M, Management of antiphospholipid syndrome in pregnant and postpartum women. 2017. www.uptodate.com.
- Cohen H, Machin SJ. Antithrombotic treatment failures in antiphospholipid syndrome: the new anticoagulants? Lupus. 2010; 19(4): 486–491.
- White CW, Thomason AR, Boyd K. Role of Novel Oral Anticoagulants in the Treatment of Antiphospholipid Syndrome. Hosp Pharm. 2016; 51(9): 759–767.
- Signorelli F, Nogueira F, Domingues V, et al. Thrombotic events in patients with antiphospholipid syndrome treated with rivaroxaban: a series of eight cases. Clin Rheumatol. 2016; 35(3): 801–805.
- Son M, Wypasek E, Celinska-Lowenhoff M, et al. The use of rivaroxaban in patients with antiphospholipid syndrome: A series of 12 cases. Thromb Res. 2015; 135(5): 1035–1036.
- Cohen H, Hunt BJ, Efthymiou M, et al. Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial, Lancet 2016, Sep. ; 3(9): e426–36.
- Pengo V, Denas G, Zopperallo G, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome, 2018. Blood. 2018; 132(13): 1365–1371.
- Woller SC, Stevens SM, Kaplan DA et al. Protocol Modification of Apixaban for the Secondary Prevention of Thrombosis Among Patients Wiih Antiphospholipid Syndrome Study. https://journals.sagepub.com.
- Corban MT, Duarte-Garcia A, McBane RD, et al. Antiphospholipid Syndrome: Role of Vascular Endothelial Cells and Implications for Risk Stratification and Targeted Therapeutics. J Am Coll Cardiol. 2017; 69(18): 2317–2330.
- Rand JH, Wu XX, Quinn AS, et al. Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug. Blood. 2010; 115(11): 2292–2299.
- Schmidt-Tanguy A, Voswinkel J, Henrion D, et al. Antithrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients. J Thromb Haemost. 2013; 11(10): 1927–1929.
- De Carolis S, Botta A, Salvi S, et al. Is there any role for the hydroxychloroquine (HCQ) in refractory obstetrical antiphospholipid syndrome (APS) treatment? Autoimmun Rev. 2015; 14(9): 760–762.
- AnTIphospholipid Antibodies (HYPATIA) Protocol: A Multinational Randomized Controlled Trial of Hydroxychloroquine versus Placebo in Addition to Standard Treatment in Pregnant Women with Antiphospholipid Syndrome or Antibodies, EudraCT number 2016-002256-25. https://www.clinicaltrialsregister.eu.
- Canaud G, Bienaimé F, Tabarin F, et al. Inhibition of the mTORC pathway in the antiphospholipid syndrome. N Engl J Med. 2014; 371(4): 303–312.
- Strakhan M, Hurtado-Sbordoni M,, Galeas N et al. Case Report 36-Year-Old Female with Catastrophic Antiphospholipid Syndrome Treated with Eculizumab: A Case Report and Review of Literature, Case Reports in Hematology, Volume 2014, Article ID 704371.
- Lonze BE, Zachary AA, Magro CM, et al. Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation. Am J Transplant. 2014; 14(2): 459–465.
- Rodríguez-Pintó I, Cervera R, Espinosa G. Rituximab and its therapeutic potential in catastrophic antiphospolipid syndrome. Ther Adv Musculoskelet Dis. 2015; 7(1): 26–30.
- Kazzaz NM, McCune WJ, Knight JS. Treatment of catastrophic antiphospholipid syndrome. Curr Opin Rheumatol. 2016; 28(3): 218–227.
- Jackson WG, Oromendia C, Unlu O, et al. Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking. Recurrent thrombosis in patients with antiphospholipid antibodies and arterial thrombosis on antithrombotic therapy. Blood Adv. 2017; 1(25): 2320–2324.
